Phase 3 Data: “Game-changing” Oral IL-23 Blocker Shows Efficacy and Safety in PsO

March 14, 2025

PsO Pipeline Watch: Alumis Inc.’s Oral TYK2 inhibitor, ESK-001, Boasts High Clearance Rates at One Year; Q & A With Dr.Andrew Blauvelt

March 12, 2025

Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO

March 10, 2025

Spesolimab (Spevigo, Boehringer Ingelheim) Improves Physical Symptoms and QofL for GPP Patients

March 8, 2025

Phase 3 Data: “Game-changing” Oral IL-23 Blocker Shows Efficacy and Safety in PsO

March 8, 2025

New Five-year Study Backs Deucravacitinib’s Safety and Efficacy in PsO

February 25, 2025

First Patient Dosed in Phase 1b Trial of VYNE’s BET Inhibitor in Moderate-to-severe PsO

February 20, 2025

Unpacking the New Expert Consensus Panel Recommendations on the Use of Deucravacitinib (Sotyktu, BMS) in Psoriasis

February 11, 2025

Fresh Off the Maui Derm Podium: Guselkumab Shows Significant Skin Clearance in Special PsO Sites

February 6, 2025

Taking on PsO With a New Photopharmaceutical Compound

February 3, 2025

Exploring NF-kB c-Rel’s Role in Psoriasis

February 3, 2025

Health Canada Accepts Arcutis’ SNDS for Roflumilast Foam 0.3% for Scalp and Body PsO

January 22, 2025